Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Target Price of $25.69 According to Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.35.

KURA has been the subject of several recent research reports. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. UBS Group reissued a “buy” rating on shares of Kura Oncology in a report on Monday, October 5th. Barclays set a $24.00 target price on shares of Kura Oncology in a research note on Wednesday. Wedbush increased their price target on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. started coverage on shares of Kura Oncology in a report on Thursday, October 1st. They issued an “overweight” rating and a $30.00 price objective on the stock.

Kura Oncology Stock Down 6.4%

Shares of NASDAQ:KURA opened at $9.08 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. Kura Oncology has a 1 year low of $7.36 and a 1 year high of $13.90. The stock has a 50-day simple moving average of $11.39 and a 200-day simple moving average of $10.32. The stock has a market capitalization of $807.77 million, a P/E ratio of -2.69 and a beta of 0.47.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Equities analysts forecast that Kura Oncology will post -3.25 earnings per share for the current year.

Insider Activity at Kura Oncology

In related news, insider Brian Powl sold 17,020 shares of Kura Oncology stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.53, for a total transaction of $179,220.60. Following the sale, the insider directly owned 152,249 shares in the company, valued at $1,603,181.97. The trade was a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Teresa Bair sold 31,487 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the sale, the insider owned 195,444 shares in the company, valued at $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 153,881 shares of company stock valued at $1,708,183. 7.60% of the stock is owned by corporate insiders.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. IFP Advisors Inc increased its holdings in shares of Kura Oncology by 136.5% in the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after buying an additional 1,467 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of Kura Oncology during the second quarter worth $113,000. Pictet Asset Management Holding SA bought a new position in Kura Oncology during the first quarter valued at approximately $96,000. E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the second quarter worth about $132,000. Finally, WINTON GROUP Ltd lifted its stake in shares of Kura Oncology by 26.2% in the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock worth $143,000 after buying an additional 2,700 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.